Setmelanotide

Mechanism

Setmelanotide is a synthetic cyclic octapeptide (sequence: Ac-Arg-cyclo[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH₂) that acts as a potent agonist at the melanocortin-4 receptor (MC4R). MC4R is a Gs-coupled receptor expressed in the hypothalamic paraventricular nucleus and other brain regions, where it regulates appetite suppression and energy expenditure. In the normal leptin-melanocortin pathway, leptin from adipose tissue signals through LEPR receptors on POMC neurons, which produce α-MSH (the endogenous MC4R agonist). POMC is processed by prohormone convertase 1/3 (encoded by PCSK1). Loss-of-function mutations in POMC, PCSK1, or LEPR disrupt this cascade, leaving MC4R unactivated and causing hyperphagia and early-onset severe obesity. Setmelanotide bypasses the upstream leptin-POMC pathway and directly activates MC4R, restoring appetite regulation and increasing energy expenditure. It also has activity at MC1R (causing skin hyperpigmentation) and MC3R, but its therapeutic effect is primarily attributed to MC4R agonism.

Evidence base

Key Published Trials

1. POMC/PCSK1 deficiency (Clément K, et al. Nature Medicine. 2020;26(7):1067-1071): Open-label trial in 10 patients. Mean weight loss 25.1% at ~1 year. 9/10 patients achieved ≥10% weight loss. NCT02896192.

2. LEPR deficiency (Huvenne H, et al. Nature Medicine. 2020;26(7):1072-1077): Open-label trial in 11 patients. Mean weight loss 12.5% at ~1 year. 7/11 patients achieved ≥10% weight loss. NCT03263710.

3. MC4R heterozygous deficiency (Collet TH, et al. Diabetes. 2021): 16-week trial showing 4.9% mean weight loss, with responders and non-responders. Less robust than POMC/LEPR deficiency populations.

4. Bardet-Biedl Syndrome and Alström Syndrome (published data from Rhythm Pharmaceuticals' expansion programme): Ongoing trials have shown meaningful weight loss signals, supporting potential label expansion.

Regulatory Status

• FDA approval: November 2020 (POMC, PCSK1, LEPR deficiency; age ≥6)
• EMA approval: 2021/2022 (similar indications)
• NICE evaluation: conducted for specific genetic obesity indications

Limitations

All pivotal trials are open-label and single-arm (no placebo control), which is a limitation. However, the rarity of these conditions (POMC deficiency: ~1 in 50,000–100,000; LEPR deficiency: ~1 in 100,000) makes randomised controlled trials extremely challenging. The natural history of these conditions — progressive severe obesity unresponsive to lifestyle intervention — provides a meaningful comparator.

Protocols

Setmelanotide (Imcivree) is supplied as a sterile injectable solution. Approved dosing:

• Adults (≥18 years): 3 mg subcutaneously once daily, with gradual titration from 1 mg starting dose.
• Adolescents and children (≥6 years, <18 years): Weight-based dosing starting at lower doses with titration.
• Administration: Subcutaneous injection, typically in the abdomen, thigh, or upper arm.

These details are for research and educational documentation. Setmelanotide is a prescription-only medicine and is not available for self-directed research use. No research peptide vendor sells setmelanotide.

UK legal status

Setmelanotide is a prescription-only medicine (POM) in the UK under the Human Medicines Regulations 2012. It is not a controlled substance under the Misuse of Drugs Act. It is not legally available as a research chemical.

Key points:

• MHRA status: Licensed medicinal product (Imcivree, Rhythm Pharmaceuticals)
• Prescription requirement: Requires a valid prescription from a registered medical practitioner, typically a specialist in endocrinology or obesity medicine
• Indication restriction: Approved only for genetically confirmed POMC, PCSK1, or LEPR deficiency obesity
• NHS funding: NICE has evaluated setmelanotide; availability through the NHS depends on commissioning decisions and may require individual funding requests
• Importation: Personal importation without a prescription is not legal

This compound is included in the Peptide Data knowledge base for educational completeness, given its significance as a melanocortin-pathway peptide. It is not available through any UK research peptide vendor.

Vendor notes

Setmelanotide is not available through any UK research peptide vendor. It is a licensed prescription medicine dispensed exclusively through pharmacies with a valid specialist prescription. No vendor profile on Peptide Data lists setmelanotide, and none should.